Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733810 · ClinicalTrials.gov registry record · NA
The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis
A NA study, sponsored by Dallas VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01733810 is a NA study that has completed, run by Dallas VA Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT01733810, a NA study, has completed, sponsored by Dallas VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.
Interventions
- OTHER Cessation of Acid Suppressing Medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2019-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733810
The ClinicalTrials.gov registry entry for NCT01733810 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dallas VA Medical Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cessation of Acid Suppressing Medications is the first listed.
NCT01733810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733810 about?
NCT01733810 is a clinical study titled "The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis". The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.
What is the current status of trial NCT01733810?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2013-02-01. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT01733810?
The interventions under investigation include: Cessation of Acid Suppressing Medications (OTHER).
Who is sponsoring clinical trial NCT01733810?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.